Who to call at Evommune, and when
Fundz watches for the moments Evommune starts buying, and tells you who to reach.
- An alert the day Evommune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Evommune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Evommune. With Fundz connected, it knows.
Contract Type
licensing
Palo AltoBiotechnologyHealth CareDescription
On November 4, 2026, Evommune, Inc. entered into an Exclusive License Agreement with Hinova Pharmaceuticals Inc. for the rights to develop and commercialize VAV1 degraders globally, with specific exclusions for Greater China. The agreement includes a one-time upfront payment of $20 million and warrants for shares valued at $10 million
Quick answer
Evommune Enters Exclusive License Agreement with Hinova Pharmaceuticals (November 4, 2026). Evommune is based in Palo Alto, California, United States.
- What agreement did Evommune announce on November 4, 2026?
- On November 4, 2026, Evommune, Inc. entered into an Exclusive License Agreement with Hinova Pharmaceuticals Inc. for the rights to develop and commercialize VAV1 degraders globally, with specific exclusions for Greater China.
- What does Evommune do?
- Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases.
- Where is Evommune based?
- Evommune is based in Palo Alto, California, United States.
- Which similar companies announced agreements around the same time?
- Wildcat DX (November 4, 2026), Nxera Pharma (November 4, 2026), Physiomics plc (November 4, 2026) and JD Technologies Global (November 4, 2026) also announced agreements within 45 days of Evommune.
Source: Fundz verified event record.
Other recent agreements in Biotechnology and Health Care
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Wildcat Defense partners with Taqtile to deploy digital tools in shipyards. (November 4, 2026)
- AbbVie secures exclusive licensing rights to Nxera’s EP4 program for inflammatory bowel disease with a $100 million payment. (November 4, 2026)
- Physiomics Wins New Contract for Drug Development Modelling Services (November 4, 2026)
- JD Technologies Global and FRIWO North America Form Strategic Partnership to Enhance U.S. Medical Market Access (November 4, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026)
Related People
Evommune signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.